Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 6/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046655 | 0.80 | PSMB8 (0.35) | ARPSMB8 | |
| SCHEMBL935523 | 0.78 | CTSS (0.40) | AKR1B1ARPGR | |
| SCHEMBL31694405 | 0.76 | PSMB8 (0.35) | HSD17B10PSMB8MEN1KMT2A | |
| SCHEMBL31215702 | 0.76 | PSMB8 (0.35) | ARPSMB8 | |
| SCHEMBL12908846 | 0.76 | GAA (0.42) | HSD17B10PSMB8RAB9ASMN1; SMN2HPGD | |
| SCHEMBL9796864 | 0.76 | PSMB8 (0.44) | HSD17B10PSMB8MEN1RAB9AKMT2A | |
| SCHEMBL935534 | 0.73 | PSMB8 (0.45) | HSD17B10PSMB8HPGD | |
| SCHEMBL140656 | 0.69 | HTT (0.56) | AR | |
| SCHEMBL29409281 | 0.69 | HTT (0.56) | AR | |
| SCHEMBL8054530 | 0.69 | DYRK1A (0.50) | VCPPSMB8RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454329-B1 | FLUORESCENT DYES AND USES THEREOF | BECKMAN COULTER INC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2454329-B1 | FLUORESCENT DYES AND USES THEREOF | BECKMAN COULTER INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-8772501-B2 | Fluorescent dyes and uses thereof | BECKMAN COULTER, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772501-B2 | Fluorescent dyes and uses thereof | BECKMAN COULTER, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130131324-A1 | Novel Fluorescent Dyes and Uses Thereof | BECKMAN COULTER, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131324-A1 | Novel Fluorescent Dyes and Uses Thereof | BECKMAN COULTER, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8367842-B2 | Fluorescent dyes and uses thereof | BECKMAN COULTER, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367842-B2 | Fluorescent dyes and uses thereof | BECKMAN COULTER, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2454329-A1 | NOVEL FLUORESCENT DYES AND USES THEREOF | Beckman Coulter, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008912-A1 | NOVEL FLUORESCENT DYES AND USES THEREOF | BECKMAN COULTER, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110014599-A1 | Novel Fluorescent Dyes and Uses Thereof | BECKMAN COULTER, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011008912-A1 | NOVEL FLUORESCENT DYES AND USES THEREOF | BECKMAN COULTER, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110014599-A1 | Novel Fluorescent Dyes and Uses Thereof | BECKMAN COULTER, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131324-A1 | Novel Fluorescent Dyes and Uses Thereof | GUSB, CHLSN, NQO1 | AKR1B1 1569/4885HSD17B10 1162/4885AR 4323/4885 |
| US-20110014599-A1 | Novel Fluorescent Dyes and Uses Thereof | GUSB, CHLSN, NQO1 | AKR1B1 1569/4885HSD17B10 1162/4885AR 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.